8-K Announcements
3Material company update
Oct 29, 2025·SEC
Material company update
Oct 17, 2025·SEC
Material company update
Jun 6, 2025·SEC
Oaktree Acquisition Corp. III Life Sciences(OACC)Earnings, Financials & Key Ratios
OACC•NASDAQ
$10.67
35.6× P/E·Price updated Jun 27, 2026
SectorFinancial ServicesIndustrySPACs & Shell CompaniesSub-IndustryHealthcare and life sciences SPACs
AboutOaktree Acquisition Corp. III Life Sciences focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to acquire companies in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors in North America and Europe. The company was incorporated in 2024 and is based in Los Angeles, California.Show more
- EBITDA-$1M-119568800.0%
- Net Income$7M+273607.2%
- EPS (Diluted)0.30+453.5%
- ROE3.81%+272271.4%
OACC Price & Volume
Oaktree Acquisition Corp. III Life Sciences (OACC) stock price & volume — 10-year historical chart
Loading chart...
Eroding Liquidity Challenges Oaktree Acquisition Shell Strategy
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Adequate
Cash Flow:Burning
Primary Risk:Liquidation deadline execution risk
"Oaktree Acquisition Corp. III operates as a pre-revenue shell entity where the primary value proposition is tied to its $204.8M in total assets held in trust. However, the company faces significant execution risk as administrative expenses have climbed to $456.5K per quarter, rapidly depleting the $1.3M in available operating cash. Investors should monitor the narrowing current ratio of 0.87, which suggests that the firm may be forced into a suboptimal business combination to avoid liquidation as its operational runway continues to contract."
Verdict Logic
the company's current ratio has compressed to 0.87, indicating that immediate liquid assets are insufficient to cover short-term liabilities while the firm remains in a pre-revenue state.
OACC Growth Metrics
Oaktree Acquisition Corp. III Life Sciences (OACC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-
Return on Capital
10 Years-0.3%
5 Years-0.3%
3 Years-0.3%
Last Year-0.6%
Peers Comparison
Key metrics vs top competitors for Oaktree Acquisition Corp. III Life Sciences (OACC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $10.67 | $262.3M | 35.57 | — | — | 3.81% | — | |
| $18.56 | $3.51B | -11.53 | 53.44% | -2554.14% | -43.94% | — | |
| $3.06 | $5.76M | -0.05 | — | — | -172.45% | — | |
| $3.52 | $1.57B | -2.44 | 26.92% | -844.46% | -54.32% | — | |
| $8.89 | $2.33B | -28.68 | 18.96% | -73.63% | -36.79% | — | |
| $149.22 | $19.79B | -44.95 | 32.88% | -40.1% | — | — |
Compare OACC vs Peers
Oaktree Acquisition Corp. III Life Sciences (OACC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
OACC SEC Filings & Documents
Oaktree Acquisition Corp. III Life Sciences (OACC) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when OACC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
OACC Frequently Asked Questions
Oaktree Acquisition Corp. III Life Sciences (OACC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is OACC profitable?
Yes, Oaktree Acquisition Corp. III Life Sciences (OACC) is profitable, generating $6.6M in net income for fiscal year 2025.
Dividend & Returns
What is OACC's return on equity?
Oaktree Acquisition Corp. III Life Sciences (OACC) has a return on equity (ROE) of 3.8%. This is below average, suggesting room for improvement.
What is Oaktree Acquisition Corp. III Life Sciences's free cash flow?
Oaktree Acquisition Corp. III Life Sciences (OACC) had negative free cash flow of $0.4M in fiscal year 2025, likely due to heavy capital investments.